DAFTAR PUSTAKA

Bai, Y., Chen, X., Hou, L., Qian, J., Jiang, T., Zhou, C., & Ciebiada, M. (2018). PD-L1 expression and its effect on clinical outcomes of EGFRmutant NSCLC patients treated with EGFR-TKIs. *Cancer Biology and Medicine*, *15*(4), 434–442.

Borgeaud, M., Parikh, K., Banna, G. L., Kim, F., Olivier, T., Le, X., & Addeo, A. (2024). Unveiling the Landscape of Uncommon EGFR Mutations in NSCLC-A Systematic Review. *Journal of Thoracic Oncology*, *19*(7), 973–983

Baiu I, Titan AL, Martin LW, Wolf A, Backhus L. (2021). The role of gender in non-small cell lung cancer: a narrative review. *J Thorac Dis*.;13(6):3816–3826

Chen WC, Cheng WC, Chen CL, Wu CY, Chen CY, Lin CC. (2024). Assessing EGFR-mutated NSCLC with bone metastasis: clinical features and optimal treatment strategy. *Cancer Med*;13(7):7152

Chen Y, Deng J, Liu Y, Wang H, Zhao S, He Y, Zhou C. (2021). Analysis of metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation. *Ann Transl Med*. 2021;9(3):206

Chen YM, Lai CH, Chang HC, Chao TY, Tseng CC, Fang WF, et al. (2021). Efficacy and prognosis of first-line EGFR-tyrosine kinase inhibitor treatment in older adults including poor performance status patients with EGFR-mutated non-small-cell lung cancer. *Cancer Manag Res*;13:7051-65

Chen N, Fang W, Zhan J, Hong S, Tang Y, Kang S, et al. (2015) Upregulation of PD-L1 by EGFR activation mediates the immune escape in EGFR-driven NSCLC: implication for optional immune targeted therapy for NSCLC patients with EGFR mutation. *J Thorac Oncol*;10(6):910-23

Cheng, Y., Wang, T., Lv, X., Li, R., Yuan, L., Shen, J., Li, Y., Yan, T., Liu, B., & Wang, L. (2020). Detection of pd-l1 expression and its clinical significance in circulating tumor cells from patients with non-small-cell lung cancer. *Cancer Management and Research*, *12*, 2069–2078.

Ding, W., Yang, P., Zhao, X., Wang, X., Liu, H., Su, Q., Wang, X., Li, J., Gong, Z., Zhang, D., & Wang, X. (2024). Unraveling EGFR-TKI resistance in lung cancer with high PD-L1 or TMB in EGFR-sensitive mutations. *Respiratory Research*, *25*(1), 1–11.

El-Ashry, A. M., Elhay, E. S. A., Taha, S. M., Salem, E. S. A. E. H. E. S., & El-Sayed, M. M. (2023). Impact of virtual group-based acceptance and commitment therapy on social adjustment and work-family conflict among intern nurses: a randomized control trial. *BMC Psychiatry*, *23*(1), 1–17

Ernst SM, Yoneda KY, Stender N, Christo M, Kim T, Chmielecki J, et al. (2023). Tobacco smoking-related mutational signatures in classifying smoking-associated and nonsmoking-associated NSCLC. *Transl Oncol* ;27:101579

Fang W, Yang Y, Ma Y, Hong S, Lin L, He X, et al. (2020). Effect of comorbidity on outcomes of patients with advanced non-small cell lung cancer undergoing anti-PD1 immunotherapy. *Med Sci Monit* ;26:e922576

Gao, W., Wang, L., Zhao, Y., & Zhu, L. (2025). The role of PD-L1 in EGFR-mutant non-small cell lung cancer. *Discover Oncology*, 16(1), 307

Ganti AK, Klein AB, Cotarla I, Seal B, Chou E. (2021). Update of Incidence, Prevalence, Survival, and Initial Treatment in Patients With Non–Small Cell Lung Cancer in the US. *JAMA Oncol* ;7(12):1824–1832

Gould MK, Munoz-Plaza CE, Hahn EE, Lee JS, Parry C, Shen E. (2017). Comorbidity profiles and their effect on treatment selection and survival among patients with lung cancer. *Ann Am Thorac Soc* ;14(10):1571-80

Herbst, R. S., Soria, J., Kowanetz, M., Fine, G. D., Hamid, O., Kohrt, H. E. K., Horn, L., Lawrence, D. P., Rost, S., Way, D. N. A., Francisco, S. S., Ave, W. K., & Carolina, N. (2016). Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. *Nature*, 515(7528), 563–567.

Hou, X., Li, M., Wu, G., Feng, W., Su, J., Jiang, H., Jiang, G., Chen, J., Zhang, B., You, Z., Liu, Q., & Chen, L. (2023). Gefitinib Plus Chemotherapy vs Gefitinib Alone in Untreated EGFR -Mutant Non-Small Cell Lung Cancer in Patients With Brain Metastases: The GAP BRAIN Open-Label, Randomized, Multicenter, Phase 3 Study. *JAMA Network Open*, *6*(2)

Han, Y., Liu, D., & Li, L. (2020). PD-1/PD-L1 pathway: current researches in cancer. *American Journal of Cancer Research* ;10(3), 727–742

Jia, Y., Li, X., Zhao, C., Ren, S., Su, C., Gao, G., Li, W., Zhou, F., Li, J., & Zhou, C. (2020). Soluble PD-L1 as a Predictor of the Response to EGFR-TKIs in Non-small Cell Lung Cancer Patients With EGFR Mutations. *Frontiers in Oncology*;10(August), 1–9

Hsu, K.-H., Tseng, J.-S., Yang, T.-Y., Chen, K.-C., Su, K.-Y., Yu, S.-L., Chen, J. J. W., Huang, Y.-H., & Chang, G.-C. (2022). PD-L1 strong expressions affect the clinical outcomes of osimertinib in treatment naïve advanced EGFR-mutant non-small cell lung cancer patients. *Scientific Reports*, *12*(1), 9753

Jin, X., Pan, Y., Cheng, C., Shen, H., Zhai, C., Yin, K., Zhu, X., Pan, H., & You, L. (2024). Optimizing first-line TKI treatment efficacy in PD-L1-positive EGFR-mutated NSCLC: the impact of antiangiogenic agents. *Frontiers in Pharmacology*;*15*(August), 1–11

Jin, Y., Shen, X., Pan, Y., Zheng, Q., Chen, H., Hu, H., & Li, Y. (2019). Correlation between

PD-L1 expression and clinicopathological characteristics of non-small cell lung cancer: A real-world study of a large Chinese cohort. *Journal of Thoracic Disease*;11(11), 4591–4601

Kementerian Kesehatan, R. (2023). Panduan Penatalaksanaan Kanker Paru. In *Komite Penanggulangan Kanker Nasional*

Kim, H. C., & Choi, C. M. (2020). Current status of immunotherapy for lung cancer and future perspectives. *Tuberculosis and Respiratory Diseases*;*83*(1), 14–19

Kumar D, Neeman, Zhu, Shiyun Sun, Hongxin, Dinesh, Raymond. (2024). Revisiting the Association of ECOG Performance Status With Clinical Outcomes in Diverse Patients With Cancer (Kaiser Permanente Research). J Natl Compr Canc Netw;23;22

Lan, B., Wang, Y., Wu, J., Wang, K., & Wang, P. (2021). The predictive and prognostic effects of PD-L1 expression on TKI treatment and survival of EGFR-mutant NSCLC: A meta-analysis. *Medicine (United States)*;100(34), E27038

Li, H., Xu, Y., Wan, B., Song, Y., Zhan, P., Hu, Y., Zhang, Q., Zhang, F., Liu, H., Li, T., Sugimura, H., Cappuzzo, F., Lin, D., & Lv, T. (2019). The clinicopathological and prognostic significance of PD-L1 expression assessed by immunohistochemistry in lung cancer: A meta-analysis of 50 studies with 11,383 patients. *Translational Lung Cancer Research*;8(4), 429–449

Lin, X., Kang, K., Chen, P., Zeng, Z., Li, G., Xiong, W., Yi, M., & Xiang, B. (2024). Regulatory mechanisms of PD-1/PD-L1 in cancers. In *Molecular Cancer* (Vol. 23, Issue 1)

Liu SV, Villaruz LC, Ravi PK, Scott Lippman J, Boland J. (2021). EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer. *Oncotarget*;8(49):86751-86.

Lee YS, Liu Q, Gozani O, Hinshaw SM, Zhang M, Nabet B, et al. (2021). Association between smoking history and tumor mutation burden in advanced non-small cell lung cancer. *Cancer Res*;81(9):2430-43

Li N, Zuo R, He Y, Gong W, Wang Y, Chen L, et al. (2024). PD-L1 induces autophagy and primary resistance to EGFR-TKIs in EGFR-mutant lung adenocarcinoma via the MAPK signaling pathway. *Cell Death Dis*;15(8):555

Meyers DE, Pasternak M, Dolter S, Grosjean H, Lim C, Stukalin I, et al. (2021). Association of performance status with survival in patients with advanced non-small cell lung cancer treated with pembrolizumab monotherapy. *JAMA Netw Open*;4(2):e2037120

Ngo, P., Cooper, W. A., Wade, S., Fong, K. M., Canfell, K., Karikios, D., & Weber, M. (2025). Why PD-L1 expression varies between studies of lung cancer: results from a Bayesian

meta-analysis. *Scientific Reports*, *15*(1), 1–10.

Palmerini, E., Agostinelli, C., Picci, P., Pileri, S., Marafioti, T., Lollini, P. L., Scotlandi, K., Longhi, A., Benassi, M. S., & Ferrari, S. (2017). Tumoral immune-infiltrate (IF), PD-L1 expression and role of CD8/TIA-1 lymphocytes in localized osteosarcoma patients treated within protocol ISG-OS1. *Oncotarget*, *8*(67)

Popat, S., Liu, S. V., Scheuer, N., Gupta, A., Hsu, G. G., Ramagopalan, S. V., Griesinger, F., & Subbiah, V. (2022). Association between Smoking History and Overall Survival in Patients Receiving Pembrolizumab for First-Line Treatment of Advanced Non-Small Cell Lung Cancer. *JAMA Network Open*;*5*(5), E2214046.

Peng S, Wang R, Zhang X, Ma Y, Zhong L, Li K, et al. (2019). EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression. *Mol Cancer*;18(1):165.

Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., O'Brien, M., Rao, S., Hotta, K., Leiby, M. A., Lubiniecki, G. M., Shentu, Y., Rangwala, R., & Brahmer, J. R. (2016). Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer. *New England Journal of Medicine*;*375*(19), 1823–1833.

Society, A. C. (2022). Lung Cancer Early Detection, Diagnosis, and Staging Can Lung Cancer Be Found Early ? *American Cancer Society*, 1–41.

Shi Y, Wang G, Liang H, Guo Y, Xu P, Jiang J. (2021). Study on PD-L1 Expression in NSCLC Patients and Related Influencing Factors in the Real World. B*iomed Res Int*:8305614

Shi, Y., Lv, W., Wang, L. M., & Hu, J. (2017). Advances of the role of lung cancer driver gene and PD-1/PD-l1 pathway interaction in the tumorigenesis and progression of non-small cell lung cancer. *Chinese Journal of Lung Cancer*;*20*(11), 781–786

Soo RA, Reungwetwattana T, Perroud HA, Lin HM, Chadjaa M, Grohé C, et al. (2024). Prevalence of EGFR mutations in patients with resected stages I to III NSCLC: results from the EARLY-EGFR study. *J Thorac Oncol*;19(10):1449-59

Saw, S. P. L., Ng, W. P., Zhou, S., Lai, G. G. Y., Tan, A. C., Ang, M. K., Lim, W. T., Kanesvaran, R., Ng, Q. S., Jain, A., Tan, W. L., Rajasekaran, T., Chan, J. W. K., Teh, Y. L., Pang, M., Yeo, J. C., Takano, A., Ong, B. H., Tan, E. H., … Tan, D. S. W. (2023). PD-L1 score as a prognostic biomarker in asian early-stage epidermal growth factor receptor-mutated lung cancer. *European Journal of Cancer*;*178*, 139–149

Tang, Q., Chen, Y., Li, X., Long, S., Shi, Y., Yu, Y., Wu, W., Han, L., & Wang, S. (2022). The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers. *Frontiers in Immunology*;1–19

Tang, Y., Fang, W., Zhang, Y., Hong, S., Kang, S., Yan, Y., Chen, N., Zhan, J., He, X., Qin, T., Li, G., Tang, W., Peng, P., & Zhang, L. (2015). The association between PD-L1 and

EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs. *Oncotarget*;*6*(16), 14209–14219

Vallejo, J., Singh, H., Larkins, E., Drezner, N., Ricciuti, B., Mishra-Kalyani, P., Tang, S., Beaver, J. A., & Awad, M. M. (2024). Impact of Increasing PD-L1 Levels on Outcomes to PD-1/PD-L1 Inhibition in Patients with NSCLC: A Pooled Analysis of 11 Prospective Clinical Trials. *Oncologist*;*29*(5), 422–430

Wo, H., He, J., Zhao, Y., Yu, H., Chen, F., & Yi, H. (2018). The efficacy and toxicity of gefitinib in treating non-small cell lung cancer: A meta-analysis of 19 randomized clinical trials. *Journal of Cancer*;*9*(8), 1455–1465

Wei, J., Liu, L., Guo, Y., Zhang, J., Wang, X., Dong, J., Xing, P., Ying, J., Yang, L., & Li, J. (2021). Clinicopathological features and prognostic implications of ASCL1 expression in surgically resected small cell lung cancer. *Thoracic Cancer*;*12*(1), 40–47.

Zhou Q, Zhang XC, Chen ZH, Yin XL, Yang JJ, Xu CR, et al. (2018). Lung cancer in never-smokers—the East Asian experience. T*ransl Lung Cancer Res*;7(4):450-63.

Zhang, T., Wan, B., Zhao, Y., Li, C., Liu, H., Lv, T., Zhan, P., Song, Y. (2019). Treatment of uncommon EGFR mutations in non-small cell lung cancer: New evidence and treatment. *Translational Lung Cancer Research*;*8*(3), 302–316

Zhang X, Zhao Y, Wang M, Yap WS, Chang AYC. Primary tumor location in lung cancer: the evaluation and administration. *Technol Cancer Res Treat*. 2022;21:15330338211072561